retatrutide news 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending ESC 2024: Retatrutide improves lipid

Staying positive and being kind to yourself during this time is crucial

Because Glp1r mRNA is also expressed in the human OB 53 , it is intriguing to explore in future studies whether intranasal administration of GLP-1 agonists 54 could potentially exert their effects by acting in the OB (a site of persistent sensitivity to GLP-1 in obesity according to our data)

As dietician Schenker points out, GLP-1 patients who manage to keep the weight off when finish taking the drugs have done so because theyve changed eating habits and mindset for good

Researchers meta-analyzed 20 large published randomized controlled studies with 83,288 patients and found a very small but not statistically significant increase in NAION in those treated with GLP-1s

Even one session can clarify whether you'd benefit from ongoing support